Romark Laboratories, L.C. Romark Laboratories, L.C. Romark Laboratories, L.C. Romark Laboratories, L.C. Romark Laboratories, L.C.

News & Events


Romark Laboratories Completes Sales Force Expansion

50 Specialty Territory Managers Across the U.S. to Promote the Company’s Products to Gastroenterologists and Primary Care Physicians

TAMPA, Fla. – April 28, 2014 – Romark Laboratories announced today that it has completed an expansion of its specialty sales force. Fifty (50) Specialty Territory Managers will promote the Company’s products and co-promoted products to gastroenterologists and primary care physicians across the United States.

"We are thrilled to have assembled a team of top-caliber Specialty Territory Managers," said Celine Rossignol, Chief Operating Officer of Romark. "With this expansion, we have significantly increased our capabilities as a sales and marketing team. We look forward to new opportunities to raise awareness of our products and their benefits to patients and healthcare providers."

Including regional managers, managed care specialists and other management and support personnel, Romark’s commercial team presently comprises approximately 65 people. The expansion, which began late in 2013, represents a three-fold increase in the size of Romark’s sales organization.

About Romark Laboratories

Romark Laboratories, L.C. is a vertically integrated biopharmaceutical company committed to the discovery and development of innovative small molecule drugs for treating infectious diseases and cancers. The Company markets Alinia® (nitazoxanide) tablets, 500 mg in the United States through a specialty sales force focused on gastroenterologists and primary care physicians.

Romark is developing a class of small molecule drugs called thiazolides. The Company’s product, NT-300 (nitazoxanide), is presently undergoing Phase 3 clinical development on a global basis for treatment of acute uncomplicated influenza. The NT-300 development program is being conducted under contract HHSO100201300004C with the U.S. Department of Health and Human Services. Other new drugs from the Company’s platform technology are proposed for treatment of viral diseases and cancers.